Cyberonics, Inc. Announces Preliminary Third Quarter Sales Results Conference Call

Strong Q3 Finish: Preliminary Q3 Sales Expected to Exceed Q2 Sales and Revised

Guidance



Apr 04, 2001, 01:00 ET from Cyberonics, Inc.

    HOUSTON, April 4 /PRNewswire/ -- Cyberonics, Inc. (Nasdaq:   CYBX) today
 announced its intention to release preliminary third quarter sales results
 after the close of the market at 4:00 p.m. EDT on Thursday, April 5, 2001.
 The Company has scheduled a simultaneous conference call and Internet
 presentation for 4:30 p.m. EDT on Thursday, April 5, 2001 to discuss the
 preliminary sales results for the third quarter ended March 31, 2001.
     Two separate phone lines are necessary to access the conference call and
 Internet presentation.  The conference call may be accessed by dialing
 800-709-3797 (if dialing from within the U.S.) or 706-679-3035 (if dialing
 from outside the U.S.).  The conference ID is 258370; the leader is Skip
 Cummins.  You may access the Cyberonics Internet presentation site via the
 PresentPLUS Gateway address
 http://www.presentplus.com/conference/gateway.html.  To test your system in
 advance, take the instant system check by clicking on the PresentPLUS Gateway
 link above, then select Browser Check from the available options.  If you
 encounter difficulty, support solutions will be provided, or you may call
 PresentPLUS toll-free at 888-966-8686 or email support@presentplus.com with
 your telephone number for an immediate call back.  Once proper compatibility
 is confirmed, the presentation site can be accessed 5 - 10 minutes prior to
 the scheduled start, beginning at 4:20 p.m. EDT on Thursday, April 5, 2001.
 Click on the link http://www.presentplus.com/conference/gateway.html, then
 click on "Attendee Login" from the available options.  The event name is
 ppcyberonics.
     Cyberonics, Inc. (www.cyberonics.com) was founded in 1987 to design,
 develop and market medical devices for the treatment of epilepsy and other
 debilitating disorders using a unique therapy, vagus nerve stimulation.  The
 Company's initial target market is epilepsy, the world's second most prevalent
 neurological disorder, which is characterized by recurrent seizures.  Vagus
 Nerve Stimulation (VNS(TM)) with the Cyberonics NCP(R) System was approved by
 the FDA on July 16, 1997 for use as an adjunctive therapy in reducing the
 frequency of seizures in adults and adolescents over 12 years of age with
 medically refractory partial onset seizures.  In addition to the U.S., the NCP
 System is currently approved for sale as a treatment for epilepsy in all the
 member countries of the European Union, Canada, Australia and other markets.
 VNS delivered by the NCP System is at various levels of investigational
 clinical study as a potential treatment for depression, obesity and
 Alzheimer's disease.  In March 2001, Cyberonics received CE Mark approval to
 sell VNS in the member countries of the European Union as a treatment for
 patients with treatment resistant or recurrent depression.
     NCP is a registered trademark of Cyberonics, Inc.  VNS is a trademark of
 Cyberonics, Inc.
 
 

SOURCE Cyberonics, Inc.
    HOUSTON, April 4 /PRNewswire/ -- Cyberonics, Inc. (Nasdaq:   CYBX) today
 announced its intention to release preliminary third quarter sales results
 after the close of the market at 4:00 p.m. EDT on Thursday, April 5, 2001.
 The Company has scheduled a simultaneous conference call and Internet
 presentation for 4:30 p.m. EDT on Thursday, April 5, 2001 to discuss the
 preliminary sales results for the third quarter ended March 31, 2001.
     Two separate phone lines are necessary to access the conference call and
 Internet presentation.  The conference call may be accessed by dialing
 800-709-3797 (if dialing from within the U.S.) or 706-679-3035 (if dialing
 from outside the U.S.).  The conference ID is 258370; the leader is Skip
 Cummins.  You may access the Cyberonics Internet presentation site via the
 PresentPLUS Gateway address
 http://www.presentplus.com/conference/gateway.html.  To test your system in
 advance, take the instant system check by clicking on the PresentPLUS Gateway
 link above, then select Browser Check from the available options.  If you
 encounter difficulty, support solutions will be provided, or you may call
 PresentPLUS toll-free at 888-966-8686 or email support@presentplus.com with
 your telephone number for an immediate call back.  Once proper compatibility
 is confirmed, the presentation site can be accessed 5 - 10 minutes prior to
 the scheduled start, beginning at 4:20 p.m. EDT on Thursday, April 5, 2001.
 Click on the link http://www.presentplus.com/conference/gateway.html, then
 click on "Attendee Login" from the available options.  The event name is
 ppcyberonics.
     Cyberonics, Inc. (www.cyberonics.com) was founded in 1987 to design,
 develop and market medical devices for the treatment of epilepsy and other
 debilitating disorders using a unique therapy, vagus nerve stimulation.  The
 Company's initial target market is epilepsy, the world's second most prevalent
 neurological disorder, which is characterized by recurrent seizures.  Vagus
 Nerve Stimulation (VNS(TM)) with the Cyberonics NCP(R) System was approved by
 the FDA on July 16, 1997 for use as an adjunctive therapy in reducing the
 frequency of seizures in adults and adolescents over 12 years of age with
 medically refractory partial onset seizures.  In addition to the U.S., the NCP
 System is currently approved for sale as a treatment for epilepsy in all the
 member countries of the European Union, Canada, Australia and other markets.
 VNS delivered by the NCP System is at various levels of investigational
 clinical study as a potential treatment for depression, obesity and
 Alzheimer's disease.  In March 2001, Cyberonics received CE Mark approval to
 sell VNS in the member countries of the European Union as a treatment for
 patients with treatment resistant or recurrent depression.
     NCP is a registered trademark of Cyberonics, Inc.  VNS is a trademark of
 Cyberonics, Inc.
 
 SOURCE  Cyberonics, Inc.